Home Font Size: 1 2 3 Send to a Friend
Morphotek is a biopharmaceutical company that develops therapeutic monoclonal antibodies through the use of its proprietary human antibody technologies. The company employs its technology to discover and develop optimized antibodies for the treatment of cancer, inflammatory and infectious diseases.
Morphotek currently has two products in clinical development and is positioned to file INDs for additional antibody products within its pipeline over the next 24 months. The company has a validated and patented antibody development platform called Human MORPHODOMA® that employs an in vitro immunization process in combination with its morphogenics whole genome evolution technology to yield high-quality target-specific antibodies that do not require any additional third party licenses for commercialization. In addition, the company’s Libradoma™ technology is a library of human antibodies that can specifically target disease-specific antigens present in diseased tissues. This platform is suitable to discover novel disease-associated targets and high-quality therapeutic mAbs for development.
As a wholly owned subsidiary of Eisai Co., Morphotek is now positioned to accelerate the development of its therapeutic antibody pipeline, as well as develop a number of additional clinical compounds.